GP 531

Drug Profile

GP 531

Alternative Names: GP 1531

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SICOR
  • Developer PeriCor Therapeutics; SICOR
  • Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Myocardial ischaemia; Unstable angina pectoris

Most Recent Events

  • 22 Jun 2009 Phase II development is ongoing in the US
  • 23 May 1997 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 22 May 1996 Phase-II clinical trials for Myocardial ischaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top